查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1446461

流感診斷市場規模、佔有率、趨勢分析報告：按測試類型、最終用途、地區、細分市場預測，2024-2030 年

Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture), By End-use (Hospitals, POCT, Laboratories), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

流感診斷市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球流感診斷市場規模將達到24.1億美元，2024年至2030年複合年成長率為5.78%。

感染監測的加強和全球慢性病盛行率的上升增加了對流感診斷的需求。例如，2022年9月，102個國家的國家流感中心和其他實驗室在2022年8月22日至2022年9月4日期間檢測了超過112,017份檢體。其中，3,879 個檢體被確定為流感病毒陽性。

包括世界衛生組織和美國衛生與公眾服務部在內的國際組織和法規正在加強遏制疾病的傳播。這些組織從事流感疫苗的綜合研究和開發。多家公司已被證實正在開發以細胞培養為基礎的疫苗，包括 VIDRL、Sequirus 和 CDC。因此，這項策略舉措可能會透過增加對細胞培養技術的需求對市場產生正面影響。

例如，2022年9月，世衛組織使用經過認證的含有NIID-MDCK的細胞株來分離人類流感病毒。該組織還對基於細胞培養的疫苗候選病毒進行了遺傳和抗原分析。此候選疫苗已通過針對細胞培養原型病毒的雙向病毒中和測試或血凝抑制測試，符合世界衛生組織的建議。細胞培養候選疫苗預計將於 2023 年準備開發和生產。

在 COVID-19 大流行期間，監測和檢測流感病毒的監測急劇減少。同樣，從 10 月到 4 月，與流感相關的住院治療也出現了趨勢。例如，從 2019 年 10 月到 2020 年 4 月，美國報告了約 19,299 例住院病例，而 2020-21 年同期僅報告了 232 例，因此在 COVID-19 高峰期間，這意味著病例減少了大約98 %。然而，世衛組織建議各國為 COVID-19 和流感病毒的同時爆發做好準備。這鼓勵地方法規整合監測計畫並加強流感疫苗接種宣傳活動。

POCT（即時檢測）在包括流感在內的感染疾病快速診斷領域的日益普及，預計將增加開發中國家對流感診斷的需求。例如，2022 年 10 月進行了一項研究，評估歐洲國家感染疾病的 POCT 覆蓋率。根據這項研究，在監測下，POCT廣泛用於高發病率的感染疾病，如愛滋病毒和流感。

流感診斷市場報告亮點

  • 按測試類型分類，快速流感診斷測試 (RIDT) 領域處於市場領先地位，佔 2023 年全球銷售額的 30.88%，預計在預測期內將呈現最快的複合年成長率。上市公司不斷推出的產品開發和新興市場使用等策略性舉措正在推動市場成長。
  • 按最終用途分類，2023 年醫院將佔據最大的市場收益佔有率。這是由於氣喘和其他慢性健康狀況等潛在健康狀況的日益增多，增加了流感併發症的風險。
  • 北美市場佔據主導地位，2023年佔總市佔率的32.69%。這是由於企業更多地獲取流感負擔資料以及該地區監測測試的增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章流感診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 流感診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析

第4章流感診斷市場：檢測類型的估計和趨勢分析

  • 2023 年和 2030 年測試類型市場佔有率
  • 細分儀表板
  • 按測試類型分類的全球流感診斷市場展望
  • 2018年至2030年市場規模、預測與趨勢分析
    • RIDT
    • RT-PCR
    • 細胞培養
    • 其他

第5章流感診斷市場：最終用途估計與趨勢分析

  • 2023 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 按最終用途分類的全球流感診斷市場展望
  • 2018年至2030年市場規模、預測與趨勢分析
    • 醫院
    • POCT
    • 研究機構

第6章流感診斷市場：按地區估計和趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • 3M Company
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Meridian Bioscience, Inc.
    • Quidel Corporation.
    • F. Hoffmann-La Roche Ltd.
    • SA Scientific Ltd
    • SEKISUI Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Hologic, Inc.
Product Code: GVR-1-68038-259-4

Influenza Diagnostics Market Growth & Trends:

The global influenza diagnostics market size is expected to reach USD 2.41 billion by 2030, registering a CAGR of 5.78% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing surveillance of the infection and the rising prevalence of chronic diseases around the world are contributing to the demand for influenza diagnostics. For instance, in September 2022, National Influenza Centres and other laboratories from 102 countries tested over 112,017 specimens between 22 August 2022 to 04 September 2022. Out of those, 3,879 tested positive for influenza viruses.

The increasing involvement of international organizations and regulations, such as WHO and the U.S. Department of Health & Human Services to control the spread of infection. The organizations are indulging in comprehensive research and development of a vaccine for influenza. It has been observed that various companies such as VIDRL, Seqirus, and CDC are developing cell culture-based vaccines. Thus, this strategic initiative is likely to have a positive impact on the market through increasing demand for cell culture technology.

For instance, in September 2022, WHO used a certified cell line including NIID-MDCK for isolating the human influenza virus. The organization also performed genetic and antigenic analysis on the cell culture-based candidate vaccine viruses. The vaccine candidates have passed two-way virus neutralization tests or hemagglutination inhibition against the cell culture prototype viruses and match the recommendation by WHO. It is anticipated that cell-culture-derived vaccine candidates will be available for development and production in 2023.

During the COVID-19 pandemic, the surveillance to monitor and detect the influenza virus drastically decreased. Similarly, the trend was witnessed in flu-related hospitalization cases between October to April. For instance, from October 2019 to April 2020, approximately 19,299 cases of hospitalization were reported in the U.S. While in the same months in 2020-21, only 232 cases were reported, hence, approximately 98% fall in the cases during the peak of COVID-19. However, WHO recommended countries be ready for the co-circulation of COVID-19 and influenza viruses. This encourages the regional regulations to integrate the surveillance program and step-up vaccination campaigns for flu.

The growing availability of point-of-care testing (POCT) in the area of rapid diagnostics of infectious diseases including flu, is expected to increase the demand for influenza diagnostics in developing countries. For instance, a study was conducted in October 2022, to assess the POCT scope for infectious diseases in European countries. As per the study, under surveillance, POCT is widely used for infectious diseases with significant incidence rates, such as HIV and flu.

Moreover, at the global level, flu activity is considerably low. As per the September 2022 report by WHO, the South African region has witnessed a significant rise in flu activity in the past few weeks, and majorly with influenza B viruses were reported. However, in regions such as Central Asia and Northern Africa, no detection of flu was reported. Decreasing incidence rates is anticipated to impact the growth of the market through low product development by companies.

Influenza Diagnostics Market Report Highlights:

  • By test type, Rapid influenza diagnostics tests (RIDTs) segment led the market and accounted for 30.88% of the global revenue in 2023 and is expected to exhibit the fastest CAGR over the forecast period. Owing to the increasing strategic initiatives such as product development and expanding the scope of usage to public events by the companies, hence, driving the market growth
  • By end-user, the hospitals accounted for largest market revenue share in 2023. This is attributed to the growing presence of underlying medical conditions such as asthma and other chronic health conditions, which increases the risk of flu complications
  • North America dominated the market and accounted for a 32.69% share in 2023 of the overall market share. Owing to the increasing accessibility of data on the influenza burden to the companies, and rising surveillance testing in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Influenza Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising geriatric population
      • 3.2.1.2. Increasing prevalence of diseases
      • 3.2.1.3. Government initiatives to counter influenza
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product safety and high development cost
  • 3.3. Influenza Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Influenza Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. RIDT
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. RT-PCR
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Cell Culture
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Influenza Diagnostics Market: End-Use Estimates & Trend Analysis

  • 5.1. End-Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Influenza Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. POCT
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laboratories
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Influenza Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. 3M Company
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Abbott Laboratories
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Becton, Dickinson and Company
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Meridian Bioscience, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Quidel Corporation.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. F. Hoffmann-La Roche Ltd.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. SA Scientific Ltd
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. SEKISUI Diagnostics
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Thermo Fisher Scientific, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Hologic, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S. influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Europe influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Germany influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Germany influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 UK influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 France influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Italy influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Spain influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Denmark influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Denmark influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Sweden influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Sweden influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Norway influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Norway influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 China influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 China influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Japan influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 South Korea influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 South Korea influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 Australia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Thailand influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 Latin America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Brazil influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 47 Brazil influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Mexico influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Argentina influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 52 MEA influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 MEA influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Africa influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 South Africa influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 UAE influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait influenza diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Influenza diagnostics market: market outlook
  • Fig. 14 Influenza diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Influenza diagnostics market driver impact
  • Fig. 20 Influenza diagnostics market restraint impact
  • Fig. 21 Influenza diagnostics market strategic initiatives analysis
  • Fig. 22 Influenza diagnostics market: Test Type movement analysis
  • Fig. 23 Influenza diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 RIDT market estimates and forecast, 2018 - 2030
  • Fig. 25 RT-PCR estimates and forecast, 2018 - 2030
  • Fig. 26 Cell Culture market estimates and forecast, 2018 - 2030
  • Fig. 27 Others estimates and forecast, 2018 - 2030
  • Fig. 28 Influenza diagnostics Market: End Use movement Analysis
  • Fig. 29 Influenza diagnostics market: End use movement analysis
  • Fig. 30 Influenza diagnostics market: End use outlook and key takeaways
  • Fig. 31 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 32 POCT market estimates and forecasts,2018 - 2030
  • Fig. 33 Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 34 Global influenza diagnostics market: Regional movement analysis
  • Fig. 35 Global influenza diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global influenza diagnostics market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 46 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 49 France market estimates and forecasts, 2018 - 2030
  • Fig. 50 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 52 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 53 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 54 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 55 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 56 China market estimates and forecasts, 2018 - 2030
  • Fig. 57 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 58 India market estimates and forecasts, 2018 - 2030
  • Fig. 59 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 62 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 63 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 64 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 65 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 67 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 69 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 70 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 71 Market share of key market players- influenza diagnostics market